Trending

#PRFX

Latest posts tagged with #PRFX on Bluesky

Latest Top
Trending

Posts tagged #PRFX

Preview
PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy PRF Technologies (Nasdaq: PRFX) filed a patent application for proprietary solar plant micro-climate forecast modeling aimed at improving short-term and intraday solar energy production forecasts.The filing protects core IP behind DeepSolar Predict, a platform the company says adapts in real time to localized environmental dynamics. PRF also announced acceptance into the NVIDIA Connect Program. The company states improved forecasts could reduce imbalance penalties, enhance revenue capture in day-ahead and intraday markets, and support better operational decisions for utility-scale solar assets.

#PRFX PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

www.stocktitan.net/news/PRFX/prf-technologi...

0 0 0 0

👁️ Safety Success: #PRFX PainReform’s drop-less OcuRing™-K ocular delivery platform showed a favourable safety profile in both preclinical and Phase I clinical studies with no treatment-related safety issues.

0 0 1 0

#PRFX hot on drop-less eye treatment and solar asset analytics, with trend likely to continue.

0 0 0 1
Preview
PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies PainReform (Nasdaq: PRFX) reported that preclinical rabbit studies and a Phase I clinical study of the OcuRing™-K drop-less sustained-release ocular delivery platform showed a favorable safety profile on Jan 12, 2026. The Phase I trial in cataract surgery patients recorded no treatment-related adverse events, no serious adverse events, and proper device positioning in all treated eyes. Preclinical results showed no ocular tissue abnormalities and no meaningful differences versus control. PainReform and majority-owned LayerBio are advancing IND-enabling activities to support next-phase clinical evaluation in the United States.

#PRFX PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

www.stocktitan.net/news/PRFX/pain-reform-s-...

0 0 0 0

Today’s most trending tickers with positive sentiment (last 24h):

#OPEN: 23
#TSLA: 19
#AAPL: 18
#SPY: 18
#GNPX: 13
#SNDK: 12
#INTC: 11
#ASTI: 9
#OKLO: 8
#RKT: 8
#CETX: 8
#NVO: 8
#EOSE: 7
#GME: 7
#NVDA: 7
#IWM: 7
#NXXT: 6
#PRFX: 6

0 0 0 0

Today’s most trending tickers with positive sentiment (last 24h):

#AAPL: 25
#OPEN: 18
#SPY: 13
#INTC: 11
#GOOGL: 10
#CETX: 9
#GOOG: 9
#AMZN: 9
#TSLA: 9
#QQQ: 8
#RKT: 8
#NXXT: 8
#ASTS: 7
#NVDA: 7
#RVMD: 6
#JPM: 6
#PRFX: 6
#JD: 5

0 0 0 0
Preview
PainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market PainReform (Nasdaq: PRFX) announced on January 5, 2026 that its DeepSolar unit launched Smart TDD, a lifecycle-wide solar Technical Due Diligence service targeting the global solar asset M&A market. Smart TDD combines 100% component and operational-history coverage, AI-driven analytics with physics-based modeling, expert engineering review, prioritized findings by financial impact, and preliminary results delivered within days. The release cites a large addressable market—$500 billion invested in 2024 and more than $60 billion of solar assets traded annually—and positions Smart TDD for use at commissioning, warranty expiry, underperformance remediation, and asset acquisitions.

#PRFX PainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

www.stocktitan.net/news/PRFX/pain-reform-s-...

0 0 0 0
Preview
PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities PainReform (Nasdaq: PRFX) announced on December 10, 2025 that its pharmaceutical division completed an R&D assessment of LayerBio’s drop-less, sustained-release ocular platform.The assessment confirmed the platform’s polymer matrix can incorporate multiple drug entities, specifically corticosteroids and NSAIDs, supporting technical feasibility for multi-drug loading. LayerBio’s pre-fabricated OcuRing is placed intraocularly during cataract surgery to provide sustained, targeted delivery at a fraction of total drug amounts used by eye-drop regimens. The company said this approach may reduce or eliminate reliance on postoperative medicated eye drops, improve compliance among elderly cataract patients, and simplify postoperative care.

#PRFX PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

www.stocktitan.net/news/PRFX/pain-reform-co...

0 0 0 0
Preview
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy PainReform (Nasdaq: PRFX) commenced development of OcuRing-K, LayerBio’s intraoperatively administered, erodible sustained‑release ocular device, and is advancing toward a Phase II clinical trial for post‑cataract pain and inflammation.OcuRing‑K delivers controlled ketorolac release to target tissues, aims to replace multi‑week eye‑drop regimens, and showed pain and inflammation reductions in preclinical studies and a Phase I evaluation with lower total drug exposure. The program targets the large cataract surgery market (~4.5M US surgeries; ~$9B global annual procedure volume) and may expand to additional ophthalmic indications pending further clinical progress and regulatory approval.

#PRFX PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy

www.stocktitan.net/news/PRFX/pain-reform-co...

0 0 0 0
Preview
PainReform Provides Business Update for the Six Months Ended June 30, 2025 PainReform (Nasdaq: PRFX) reported significant developments for H1 2025, marking a strategic shift into both pharmaceuticals and renewable energy. The company completed a majority investment in LayerBio, acquiring OcuRing™-K, a dropless cataract therapy targeting a $9B global market. Their pharmaceutical pipeline includes ongoing R&D for PRF-110, which showed early positive efficacy in postoperative pain.The company's DeepSolar division achieved notable milestones, including the completion of MyDeepSolar app, acceptance into NVIDIA Connect Program, and conversion of a 92MW pilot with Econergy into their first commercial agreement. Financially, PainReform reduced its net loss to $2.3M from $12.8M year-over-year, maintaining $3.5M in cash and $1.5M in positive working capital.

#PRFX PainReform Provides Business Update for the Six Months Ended June 30, 2025

www.stocktitan.net/news/PRFX/pain-reform-pr...

0 0 0 0

JUST IN: ( NASDAQ: #PRFX ) US Companies Moving the Markets, Morning edition <br>Tue, Aug 19, 2025 as of 10.00 am ET

0 0 0 0

Breaking News: ( NASDAQ: #PRFX ) PainReform/DeepSolar Accepted into NVIDIA Connect Program

0 0 0 0
Preview
50% Better Solar Weather Forecasting: PainReform's DeepSolar Joins Elite NVIDIA AI Program for Clean Energy DeepSolar gains access to NVIDIA's AI tools to enhance solar forecasting accuracy by 50% and reduce O&M costs by 30%. Platform aims to optimize PV system performance and energy trading.

#PRFX PainReform/DeepSolar Accepted into NVIDIA Connect Program

www.stocktitan.net/news/PRFX/pain-reform-de...

0 0 0 0
Preview
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio PainReform (Nasdaq: PRFX) has announced a strategic investment agreement with LayerBio Inc., acquiring a majority equity stake and board position for up to $3 million in milestone-based investments. The deal expands PainReform's non-opiate pain management pipeline into ophthalmology.LayerBio's lead product, OcuRing™-K, is a sustained-release intraocular ring delivering anti-inflammatory and analgesic agents post-cataract surgery, targeting a market of 3 million annual U.S. procedures. The initial investment of $600,000 will support a planned Phase II clinical trial, with remaining funds disbursed based on development milestones.The transaction, expected to close by July 2025, will maintain LayerBio's current management under CEO Dr. Ken Mandell, a Harvard-trained ophthalmologist and biotechnology entrepreneur with extensive experience in drug delivery innovations.

#PRFX PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

www.stocktitan.net/news/PRFX/pain-reform-lt...

0 0 0 0
SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new downtrend in Average Directional Index, Mon Jun 23rd - #TELO #PRFX #DTST #TALK #SJ #RVPH #PLRX #CERT #BTCT #ATOM #WGO #NL #MLNK #HBI #BCSF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0
Preview
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales Blade Ranger Ltd. (TASE: BLRN) announced a significant milestone in its transaction with PainReform (NASDAQ: PRFX) regarding the sale of its DeepSolar operations. Following increased software sales, Blade Ranger has received 685,004 warrants exercisable at $0.01 per share, with PainReform's shares trading at approximately $1.91. The March 2025 agreement initially provided Blade Ranger with approximately 9.9% equity in PainReform and 3.08 million warrants. Currently, Blade Ranger holds shares and warrants worth approximately $2 million based on the current share price, with the matured warrants valued at approximately NIS 4.5 million.

#PRFX Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

www.stocktitan.net/news/PRFX/blade-ranger-c...

0 0 0 0
Preview
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar Projects PainReform (NASDAQ: PRFX) has launched a strategic pilot program with Econergy Renewable Energy to implement its DeepSolar™ AI platform at one of Romania's largest solar facilities. The pilot will take place at Econergy's 92-megawatt photovoltaic plant in Parau, Romania.The DeepSolar™ platform will analyze real-time and historical data to optimize operational efficiency and energy yield. Upon successful completion, the program may expand across Econergy's portfolio, potentially reaching 1 Gigawatt of total capacity. The partnership aims to demonstrate how AI-powered solutions can enhance performance and reduce costs in utility-scale solar operations.Econergy, headquartered in Israel, operates across Europe with approximately 1 gigawatt of photovoltaic capacity either operational or under construction.

#PRFX PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar Projects

www.stocktitan.net/news/PRFX/pain-reform-la...

1 0 0 0
SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Apr 10th - #SOUN #AG #WULF #JBLU #AREB #VRN #WHLR #PRFX #IQ #WRAP #WOLF #NVAX #TTNP #SMR #RIG #RGTI #QBTS #PCT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

2 0 0 0

News; ( NASDAQ: #PRFX ) PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

0 0 0 0
Wednesday’s Runners, 2 Fresh Plays **Wednesday in Review:** We made out pretty well yesterday with the options ideas we formulated for **our premarket report**. We went with just a pair of ideas, but they both played out pretty well. Early on, the SPY Puts ran, prior to the tariff pause that was announced later in the afternoon. Today, we’re going to flip again, anticipating the SPY to pare some of those gains early, before seeing another bounce at some point throughout the day. As for yesterday’s targets, we had the **SPY 04/09 $489-487 Puts** and the **DAL Weekly $35-36 Calls** put up these figures on the day: ** SPY 04/09 $489-487 Puts $489: **1.88-4.04 (+115%) **$488:** 1.73-3.70 (+114%) **$487:** 1.57-3.37 (+115%) _____ **DAL Weekly $35-36 Calls** **$35:** 3.18-6.58 (+107%) **$35.50:** 2.68-8.90 (+232%) **$36:** 1.03-9.00 (+774%) * * * **Fresh Options Ideas: SPY 04/10 $532-534 Calls* KMX 04/17 $77.50-72.50 Calls** _*Trading options contracts on their day of expiration should only be attempted by experienced traders _ * * * ** Venus Concept Inc. (NASDAQ:VERO) – Recap:** VERO came off of our extended watchlist yesterday and went down as the NASDAQ’s biggest mover of the day. While most of that figure was in the major gap-up, we still saw the stock trade intraday from 7.10-9.97, which marks a rise of 40% * * * **Extended Watchlist:** **ELAB, PRFX, ICCT, BTOG, RSLS, KTTA, WHLR, HYFM**

Wednesday’s Runners, 2 Fresh Plays Wednesday in Review: We made out pretty well yesterday with ...

bluehorseshoestocks.com/wednesdays-runners-2-fre...

#Daily #Report #BTOG #DAL #ELAB #HYFM #ICCT #KMX #KTTA #PRFX #RSLS

Event Attributes

0 0 0 0
Wednesday’s Runners, 2 Fresh Plays **Wednesday in Review:** We made out pretty well yesterday with the options ideas we formulated for **our premarket report**. We went with just a pair of ideas, but they both played out pretty well. Early on, the SPY Puts ran, prior to the tariff pause that was announced later in the afternoon. Today, we’re going to flip again, anticipating the SPY to pare some of those gains early, before seeing another bounce at some point throughout the day. As for yesterday’s targets, we had the **SPY 04/09 $489-487 Puts** and the **DAL Weekly $35-36 Calls** put up these figures on the day: ** SPY 04/09 $489-487 Puts $489: **1.88-4.04 (+115%) **$488:** 1.73-3.70 (+114%) **$487:** 1.57-3.37 (+115%) _____ **DAL Weekly $35-36 Calls** **$35:** 3.18-6.58 (+107%) **$35.50:** 2.68-8.90 (+232%) **$36:** 1.03-9.00 (+774%) * * * **Fresh Options Ideas: SPY 04/10 $532-534 Calls* KMX 04/17 $77.50-72.50 Calls** _*Trading options contracts on their day of expiration should only be attempted by experienced traders _ * * * ** Venus Concept Inc. (NASDAQ:VERO) – Recap:** VERO came off of our extended watchlist yesterday and went down as the NASDAQ’s biggest mover of the day. While most of that figure was in the major gap-up, we still saw the stock trade intraday from 7.10-9.97, which marks a rise of 40% * * * **Extended Watchlist:** **ELAB, PRFX, ICCT, BTOG, RSLS, KTTA, WHLR, HYFM**

Wednesday’s Runners, 2 Fresh Plays Wednesday in Review: We made out pretty well yesterday with ...

bluehorseshoestocks.com/wednesdays-runners-2-fre...

#Daily #Report #BTOG #DAL #ELAB #HYFM #ICCT #KMX #KTTA #PRFX #RSLS

Event Attributes

0 0 0 0
Preview
Major Pivot: Pharma Company PainReform Transforms into AI-Powered Solar Tech Player AI-driven solar optimization platform acquisition marks PainReform's strategic entry into smart energy management. See how this transformation targets recurring revenue.

#PRFX PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization Market

www.stocktitan.net/news/PRFX/pain-reform-ex...

0 0 0 0
Preview
PainReform Provides Year-End Business Update PainReform (PRFX) provided its 2024 year-end business update, highlighting two main developments: a setback in Phase 3 clinical trials for PRF-110 (post-operative pain relief drug) and the acquisition of DeepSolar, an AI-driven solar analytics platform.Financial highlights for 2024:R&D expenses increased to $11.7M (vs $6.0M in 2023)G&A expenses decreased to $3.0M (vs $3.6M in 2023)Net loss widened to $14.6M (vs $9.3M in 2023)Working capital stood at $2.0MThe company raised $0.9M through its ATM program and believes it now exceeds Nasdaq's minimum shareholders' equity requirement of $2.5M following the DeepSolar acquisition. The company plans to address PRF-110's 24-hour data gap using advanced testing models while exploring strategic partnerships in the clean energy sector through DeepSolar.

#PRFX PainReform Provides Year-End Business Update

www.stocktitan.net/news/PRFX/pain-reform-pr...

0 0 0 0
Preview
PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics PainReform (NASDAQ: PRFX) has completed its acquisition of DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition positions PainReform in the high-growth clean energy sector while maintaining its pharmaceutical focus.DeepSolar's SaaS platform provides AI-powered solutions for solar energy asset management, promising to reduce maintenance costs by up to 30%. The platform integrates with SCADA systems for monitoring and predictive maintenance, targeting utility-scale operators, power producers, and residential users.As consideration, BladeRanger received 178,769 ordinary shares (9.9% of PainReform) and 223,792 pre-funded warrants. Additional securities will be issued after the April 3, 2025 shareholders meeting, including milestone warrants and warrants-A/B, with a 9.99% ownership cap.

#PRFX PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

www.stocktitan.net/news/PRFX/pain-reform-co...

0 0 0 0
SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Feb 18th - #SLDP #GCL #QBTS #PRFX #IQ #JBLU #VNET #BB #BTG #SERV #BBAI #BLDP #FCEL #KULR #RGTI #RR #SMR #STAI #WULF #ALLO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0
Preview
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity PainReform (PRFX) has executed a definitive agreement to acquire DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition, expected to close by February 2025, represents a strategic expansion while maintaining the company's commitment to drug delivery technologies.DeepSolar's AI-powered platform optimizes solar energy assets, reducing operational costs by up to 30% and maximizing energy production. The platform serves both B2B (utility-scale operators) and B2C (residential) markets through its 'My DeepSolar' app.As consideration, BladeRanger will receive 178,769 ordinary shares (9.9% of PainReform), plus various warrants totaling over 3 million potential shares. The agreement includes a 9.99% ownership cap and a 90-day restriction on new share issuances by PainReform. The company must register these securities with the SEC within 60 days of closing.

#PRFX PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

www.stocktitan.net/news/PRFX/pain-reform-ex...

0 0 0 0
Preview
PainReform's PRF-110 Trial Shows Mixed Results: Strong 48-Hour Pain Relief But Misses Primary Endpoint PainReform's bunionectomy pain treatment demonstrated significant early efficacy but falls short of 72-hour endpoint. Company initiates R&D refinement and strategic review.

#PRFX PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

www.stocktitan.net/news/PRFX/pain-reform-pr...

0 0 0 0